What Berlithion 600 Treats: Main Uses and Benefits

---

The primary therapeutic application of Berlithion 600 (Thioctic Acid) is generally focused on providing relief from the disruptive symptomatic manifestations associated with diabetic polyneuropathy, specifically helping with pain and sensory disturbances.

Relieving Neuropathic Discomfort and Symptom Burden

The medication generally assists with managing symptoms of increased neurological or muscular activity, such as the burning sensation, persistent tingling (paresthesia), and neuropathic pain often felt in the extremities. It is commonly used across conditions presenting with acute episodes or when symptoms become more disruptive during flare-ups. This supportive relief contributes to easing the overall symptom load, and may help patients cope more steadily with symptom fluctuations that interfere with routine activities.

“It supports general well-being during symptomatic phases and assists with maintaining functional stability.”

---

Quick Fact: Therapeutic Support

Therapeutic Domain	Primary Symptom Axis
Symptomatic Management	Symptoms that create noticeable physiological strain
Condition Context	Conditions characterized by periods of heightened symptoms
Patient Benefit	Contributes to improved comfort during symptomatic periods

Regulatory References

1. Philippine Food and Drug Administration

Berlithion 600, which contains the active substance thioctic acid (also known as alpha-lipoic acid), is typically prescribed for the treatment of diabetic polyneuropathy (nerve damage caused by diabetes).

---

Who Can Use Berlithion 600?

Patient Group	Indication
Adults	Treatment of symptoms of peripheral nerve damage in diabetic patients.

---

Who Cannot Use Berlithion 600?

This medication is not suitable for everyone and is generally contraindicated in the following cases:

• Hypersensitivity or Allergy: Individuals with a known allergy to thioctic acid or any other ingredient present in the formulation should not use Berlithion 600.
• Children and Adolescents: Due to a lack of adequate clinical data and experience concerning safety and efficacy in these age groups, the use of this medicine is not recommended for children and adolescents.
• Pregnancy and Breastfeeding: Use during pregnancy and while breastfeeding is generally discouraged as there is insufficient data on potential risks to the fetus or infant. A healthcare provider must carefully weigh the benefits against the risks in these situations.

Patients should always inform their doctor about any existing chronic diseases, metabolic disorders, or if they are taking other medications, as this can influence the safety and efficacy of the treatment.

Interactions with other medicines and products

The interaction profile of Berlithion 600 (Thioctic Acid) is primarily structured by its potential impact on blood glucose management and its chemical action as a metal chelator, as defined in regulatory documents.

Pharmacodynamic Interactions Co-administration with Insulin and other Oral Anti-diabetic Agents is formally documented to result in a potentiation of the blood-sugar lowering effect. This additive pharmacodynamic effect increases the potential risk of developing hypoglycemia, requiring careful attention to documented blood glucose changes.

Restrictions Due to Chemical Interaction Thioctic Acid is recognized as a metal chelator, which necessitates constraints on administration timing. To mitigate the reduction in the active substance's absorption, the oral form of Berlithion 600 must be administered separately from Iron-containing products and Magnesium preparations. This chelation property also underlies the documented interaction with Cisplatin, where co-administration causes a loss in the efficacy of the anti-cancer drug.

Substance and Population Constraints Regular intake of Alcohol is restricted as it can formally impair the overall success of treatment and is designated a significant risk factor for the progression of neuropathic pathology. A population-specific caution exists for certain genetically predisposed diabetic patients regarding an increased risk of Insulin Autoimmune Syndrome (IAS) when treated with Thioctic Acid.

How Berlithion 600 Works

Berlithion 600 (Thioctic Acid) exerts its action through a fundamental dual mechanism that simultaneously addresses cellular energy deficits and Reactive Oxygen Species (ROS) and subsequent oxidative modifications, leveraging the Thioctic Acid/Dihydrolipoic Acid redox pair.

---

Dual Action: Metabolic Cofactor and Energy Support

This domain relates to the molecule's role as an essential cofactor for key mitochondrial enzymes, including the Pyruvate Dehydrogenase Complex (PDHC). By acting as a cofactor for these enzyme systems, Thioctic Acid enhances the flow of substrates into the Krebs cycle, which directly facilitates the cell's ATP (energy) generation by supplying required cofactors.

---

️ Direct Cellular Antioxidant Defense and Regeneration

The molecule functions as a broad-spectrum antioxidant, directly scavenging Reactive Oxygen Species (ROS) and other harmful free radicals across both aqueous and lipid environments. Crucially, its reduced form regenerates the body's native, depleted antioxidants like Glutathione and Vitamin E, which contributes to the cellular defense against oxidative stress.

---

Modulation of Protective Signaling Pathways

The mechanism includes the modulation of transcriptional factors, notably the activation of Nrf2 leading to the transcription of endogenous protective enzymes and the inhibition of NF-κB that results in reduced pro-inflammatory signaling. This systemic modulation of gene expression contributes to the protection of vulnerable cell structures and the continuity of function for energy-dependent systems, such as the Na+/K+-ATPase required for nerve conduction velocity (NCV).

How to Use Berlithion 600

The usage of Berlithion 600 (Thioctic Acid) is structured as a two-phase protocol, transitioning between an intensive treatment course delivered intravenously and a long-term continuation phase administered orally. This methodology ensures a consistent, high-level approach to systemic administration.

---

Administration and Dosage Regimen

The medicine is administered using a standardized 600 mg once-daily dose across both phases, a concentration established for systemic efficacy in adult patient groups.

Administration Phase	Route	Daily Dose	Typical Duration
Initial Treatment	Intravenous (IV) Infusion	600 mg	2 to 4 weeks
Continuation Therapy	Oral Administration	600 mg	Long-term

---

Procedural and Contextual Use

Initial IV Administration: The concentrate for infusion is utilized for the short-term initial treatment. The 600 mg solution is administered slowly over a minimum of 30 minutes and the infusion time must not be exceeded. Due to the active substance’s photosensitivity, the solution requires protection from light during the administration process. Furthermore, the infusion should be started immediately after the vial has been opened.

Continuation Oral Use: Following the initial IV course, treatment transitions to the oral form for chronic management. The 600 mg tablets or capsules are typically taken once daily. To optimize absorption, the oral dose is generally taken on an empty stomach, often about 30 minutes before the first meal. The use of this medicine is indicated for adults.

Research Evidence / Overview of Studies for Berlithion 600

Evidence for Symptom Relief in Diabetic Nerve Damage

Thioctic Acid (Alpha-Lipoic Acid) was studied for its application in conditions characterized by the uncomfortable symptoms associated with diabetic polyneuropathy. The research primarily relies on Randomized Controlled Trials (RCTs), where patient groups receiving the medicine were compared against groups receiving an inactive substance (placebo). These trials examined patient-reported outcomes describing perceived discomfort, specifically focusing on common issues like burning sensations, tingling, and pain in the extremities, often using standardized symptom scores.

These studies monitored how symptoms evolved in the observed populations, with findings describe patterns observed in the studies related to temporary symptom changes. Research highlights changes measured during the study period, primarily over short-term intervals of a few weeks or intermediate periods of up to six months. However, evidence is limited regarding whether these observed changes was associated with a sustained change in underlying nerve function.

Comparing Intravenous and Oral Study Findings

Research was conducted during periods of increased symptom activity, utilizing two main approaches: short-term administration via the intravenous (IV) form and longer-term use of the oral tablet form. Studies explored the effects in patients receiving the medicine through infusion, which typically occurred over brief, defined time intervals. Separate research also examined the oral form over several months to understand potential differences in how the compound was observed in the body and its connection to outcomes related to physical discomfort.

Findings were mixed when comparing data between the intravenous and oral forms, which has contributed to the evidence quality varying across studies. For the oral form, the follow-up durations were limited in some key studies, which may contribute to the mixed nature of the findings observed in some studies regarding long-term physical measurements of nerve function.

Data on Extended Use and Long-Term Outcomes

Studies explored responses over defined time intervals, with the majority of the available data focusing on short- to intermediate-term relief, typically up to 6 months. There are, however, reports of research with extended follow-up, with trials studies explored periods of up to two and four years. These longer-duration studies was studied for the purpose of tracking the evolution of objective neurological measures, such as formal tests of nerve function, in the observed populations.

Long-term effects are not fully established, and limited information is available for long-term outcomes. Research also notes that comparative evidence is lacking for certain long-term outcomes evaluated in similar study contexts. The extended-duration research contributes to the broader evidence landscape, but the data are still emerging on whether consistent functional changes, as opposed to temporary symptom changes, was observed in the study groups over many years.

Research Consistency and Remaining Evidence Gaps

The evidence contributes to understanding symptom patterns, but the certainty remains low across all assessed outcomes. Research highlights that the evidence quality varies across studies, partly due to the challenge of studying a condition where symptoms may vary in intensity. Key research limitations include the fact that results apply only to the populations studied, meaning findings describe group patterns, not personal outcomes. Research does not determine whether an individual will respond similarly.

The evidence is limited regarding the effect on objective measures of nerve health; for instance, findings were mixed when studies monitored changes in Nerve Conduction Studies (NCS). Furthermore, data for certain groups remain insufficient, and research has provided limited information for long-term outcomes. Research is ongoing to address these gaps and provide further context on how symptoms change over time.

Common questions about Berlithion 600 (FAQ)

---

Q: Does Berlithion 600 cause stomach problems or nausea?

According to official product information, the medicine may cause effects related to the stomach and intestines. These are generally documented as uncommon side effects and may include symptoms such as nausea or vomiting.

---

Q: Can Berlithion 600 affect my sleep?

Regulatory documents do not specifically list changes to sleep patterns. However, they do document uncommon side effects related to the central nervous system, such as dizziness. The official information notes that if a person experiences dizziness, the ability to drive or operate machinery may be impaired.

---

Q: Is Berlithion 600 safe to use with blood pressure medication?

Official drug labels prioritize interactions with anti-diabetic agents and insulin due to the potential risk of low blood sugar. While a specific negative interaction with common blood pressure medications is generally not listed in the official product documents, it is generally described as standard practice to ensure that a healthcare provider reviews all medicines being used, as they can assess individual situations.

---

Q: What happens if I miss taking a dose of Berlithion 600?

The Patient Information Leaflet (PIL) states that a missed dose is typically taken as soon as the user remembers. The PIL also clarifies that taking two doses simultaneously to compensate for a missed dose is not recommended.

---

Q: Can Berlithion 600 be taken alongside supplements like B vitamins?

Official documents caution against taking this medicine at the same time as mineral preparations, specifically those containing iron or magnesium, because this can reduce the absorption of the active ingredient. Interactions with other vitamin supplements, such as B vitamins, are generally not specifically listed in the regulatory documents.

---

Q: Does Berlithion 600 interact with thyroid medications?

Some regulatory-linked resources indicate that the active ingredient, thioctic acid, may interact with thyroid hormone replacement therapy. This potential interaction is noted because the medicine may affect the results of thyroid function tests, a situation usually managed by the prescribing physician.

---

Q: Are there any known side effects related to the heart?

Official product documents note that changes in heartbeat or other non-specific cardiac symptoms have been reported in rare cases. These effects are primarily related to the use of the intravenous infusion and are described in regulatory texts as occurring when the intravenous infusion is administered too rapidly.

---

Q: Is Berlithion 600 approved by the FDA?

The active ingredient in this product, alpha-lipoic acid (or thioctic acid), is not approved by the US Food and Drug Administration (FDA) as a drug for the treatment of any specific condition. It is, however, widely available and used as a medicinal product in many other countries and is sold as a dietary supplement in the US market.

---

Q: How long does Berlithion 600 stay in your system?

According to pharmacokinetic data detailed in regulatory documents, the active ingredient, alpha-lipoic acid, is cleared from the body relatively quickly. It is generally known to have a short plasma half-life, which often ranges between 30 minutes and 1.5 hours, depending on the specific formulation.

---

Q: Are there any restrictions on driving or operating machinery while using Berlithion 600?

Official product information advises caution regarding driving and operating machinery. The ability to perform these tasks may be affected if the user experiences side effects such as dizziness or symptoms of low blood sugar (hypoglycemia), as noted in regulatory documents.

Official Storage and Disposal Requirements

The storage of Berlithion 600 (Thioctic Acid) is defined by regulatory guidelines to protect the medicine's stability and integrity. The product must be stored below 30 C and should not be refrigerated or frozen. Protection from light and moisture is mandatory, requiring the medicine to be kept in its original package and, for tablets, the container must remain tightly closed.

Specific stability rules apply to the infusion solution: the diluted solution is stable for up to 6 hours only when protected from light during handling and administration.

All medicines, including Berlithion 600, must be stored out of the sight and reach of children.

Disposal must adhere to pharmaceutical waste protocols. The product must not be thrown away via wastewater or household trash; disposal of unused or expired medicine must follow local requirements for controlled pharmaceutical waste.